This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Sulbutiamine
Lipid-soluble synthetic dimer of thiamine that crosses the BBB and raises brain thiamine plus pyrophosphate; chronic dosing upregulates D1…
Aliases (7)
Overview
What is Sulbutiamine?
Sulbutiamine is a synthetic, lipophilic derivative of vitamin B1 (thiamine) developed in Japan. Two thiamine molecules linked by a sulfur bridge cross the blood-brain barrier far more efficiently than thiamine itself. It is used in France as Arcalion for asthenia (functional fatigue) and off-label as a nootropic.
Key Benefits
Reduces mental and physical fatigue (especially functional asthenia), improves motivation and mood (mild dopaminergic boost), enhances memory and reaction time in some studies, and may help with attention in low-dopamine states.
Mechanism of Action
Sulbutiamine crosses the BBB and is converted to thiamine derivatives that act as cofactors in glucose metabolism and the pentose phosphate pathway. It also upregulates D1 dopamine receptor density in the prefrontal cortex and modulates cholinergic and glutamatergic transmission, contributing to the wakefulness and motivation effects.
Pharmacokinetics
▸Brand options7 known
StatusOTC dietary supplement (US); prescription Rx as Arcalion in France/Asia/Eastern Europe; not scheduled US/UK/EU
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
functional pairing — caffeine adds peripheral arousal + adenosine block; theanine smooths edge; sulbutiamine adds drive/motivation. Three different mechanism…
(300-600 mg): cholinergic substrate — sulbutiamine's chronic ACh-release effect is substrate-limited; alpha-GPC supplies the choline. Logical pairing on the …
(1-2 g): tyrosine is the rate-limiting precursor for dopamine synthesis. Under cognitive stress, tyrosine prevents DA depletion; sulbutiamine raises D1 sensi…
another PRN-only dopaminergic with even faster tolerance (~3 days). Not literally synergistic but they share the "PRN drawer" use case and don't conflict mec…
mechanistically distinct (DAT, orexin, histamine vs D1 receptor density). Plausibly additive on motivation. Reddit anecdotes suggest the combination feels "c…
Caution. Selegiline at nootropic doses (1-2.5 mg) is selective MAO-B but loses selectivity at higher exposures (Emsam 9-12 mg patch reaches MAO-A inhibition)…
both work on dopaminergic systems (bromantane via TH/AADC enzyme upregulation increasing DA *synthesis*; sulbutiamine via D1 receptor density increasing *sen…
stacking sulbutiamine on top of a DA-releaser is over-determined and likely not additive for benefit (D1 saturated) but is additive for jitter/anxiety/sleep …
avoid entirely (manic switch risk per case reports).
no conflicts.
redundant but not harmful. Sulbutiamine itself adds CNS-active thiamine, so additional B1 isn't gaining much.
different system, different time of day, no conflict.
Quality Indicators
Tested third-party COA
Reputable brands publish a Certificate of Analysis for identity, potency, and contaminant testing.
GMP-certified manufacturing
Look for cGMP / NSF / USP certifications on the label.
Proprietary blends
Avoid products that hide individual ingredient amounts inside a "proprietary blend."
No origin or sourcing info
Unbranded or no-COA capsules from anonymous sellers carry quality and adulteration risk.
What to Expect
- Week 1Baseline tolerability. Most chronic-use supplements have no acute signal.
- Week 2-4Subtle baseline shift — sleep quality, mood, recovery markers.
- Week 4-8Reach steady state. Re-assess subjective + objective markers.
- Month 3+Long-term maintenance dose if benefit confirmed; otherwise stop.
Side Effects & Safety
- Common (>10% with daily use): mild GI (nausea, loose stool, mild abdominal pain), headache (dose-dependent, usually resolves with food), insomnia if dosed too late.
- Less common (1-10%): skin rashes (dose-related, mostly at 600+ mg/day), eczema-like flares in predisposed users, paradoxical drowsiness/fatigue with daily use (likely the same D1 desensitization that produces tolerance), bladder discomfort, vertigo, sore throat.
- Rare-serious (<1%):
- Manic switch in bipolar / latent bipolar: at least two case reports in the literature — Bulut et al. case report ("Manic Attack Possibly Triggered by Sulbutiamine") and Douzenis et al. 2006 (World J Biol Psychiatry) describing a bipolar patient who developed compulsive escalating sulbutiamine use ("addiction") and disrupted bipolar treatment outcome. Anyone with bipolar I or II, family history of bipolar, or prior SSRI-induced hypomania should not use sulbutiamine.
- Psychological dependence / compulsive use: documented in the Douzenis bipolar case but appears rare in non-bipolar users. Pattern is dose-escalation seeking the original first-week effect after tolerance.
- Specific watch periods: First 1-2 weeks for tolerance trajectory; first 30 days for skin reactions; lifetime watch for bipolar emergence in any user with affective vulnerability.
No reports of: Stevens-Johnson syndrome, hepatotoxicity, cardiotoxicity, seizure threshold lowering, serotonin syndrome.
References
Sulbutiamine — Wikipedia
synthesis history (Japan 1950s, marketed in France by Servier 1973), 1989 100 mg discontinuation, half-life 5 hr, clinical indications.
View StudyStarling-Soares et al. 2020, *J Nutr Metab* — Role of the Synthetic B1 Vitamin Sulbutiamine on Health (PMC7210561)
comprehensive review; mechanism, asthenia trials, ED study, Loo depression trial summary.
View StudyTrouvé R, Nahas G — Modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in rat brain (PMID 10996447)
D1 upregulation +26% PFC / +34% cingulate; acute vs chronic mechanism distinction.
View StudyBizot et al. 2005, *Pharmacol Biochem Behav* — Chronic sulbutiamine improves object recognition memory + reduces dizocilpine amnesia (PMID 15951087)
9-week 12.5/25 mg/kg rodent model; cognitive/memory + cholinergic mechanism.
View StudyLoo et al. 2000, *L'Encephale* — Sulbutiamine 600 mg + clomipramine for psycho-behavioral inhibition in major depression (PMID 10858919)
8-week multicentric RCT; "no antidepressant, but accelerates rehabilitation."
View StudySevim et al. 2017, *Mult Scler Relat Disord* — Sulbutiamine for MS fatigue
60-day open-label, FIS 77→60.5, DMT-dependent benefit.
View StudyArslan & Ordu 2026, *Bratislava Med J* — Sulbutiamine in cerebral ischemia rat model
most recent meaningful paper; BDNF/VEGF-A/HIF-1α elevation, anti-neuroinflammatory.
View StudyBulut et al. — Manic Attack Possibly Triggered by Sulbutiamine: Case Report
bipolar manic switch documentation.
View StudyDouzenis et al. 2006, *World J Biol Psychiatry* — Sulbutiamine, an "innocent" OTC drug, interferes with bipolar treatment (PMID 16861144)
addiction/dose-escalation case in bipolar patient.
View StudyBalzamo & Vuillon-Cacciuttolo — sulbutiamine in sports, doping monitoring (PMID 21204296)
confirms WADA-monitored but not banned.
View StudyVolvert et al. 2008, BMC Pharmacol — Benfotiamine vs lipid-soluble disulfide derivatives (PMC2435522)
confirms benfotiamine does NOT raise brain thiamine; sulbutiamine does. Mechanistic distinction.
View StudyAbd-Eldayem et al. 2023, *Chem Biol Interact* — Sulbutiamine in diabetic nephropathy
PKC/TLR-4/NF-kB downregulation; off-target indication.
View StudyReddit r/Nootropics tolerance threads (synthesized via SuperMindHacker, NootropicsExpert, Wholistic Research)
community tolerance + cycling consensus.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.